慢性丙型肝炎再次抗病毒治疗持续病毒学应答率的影响因素
Factors affect the sustained virologic response rate of re-antiviral treatment for chronic hepatitis C
出处
《肝脏》
2004年第1期58-60,共3页
Chinese Hepatology
参考文献36
-
1Kao JH, Lai MY, Chen PJ, ct al. Prolonged interferon treatment after combination interferon and ribavirin therapy in patients with chronic hepatitis C: a clinical trial of interferon relapsers and non-responders. J Formos Med Assoc, 2001,100 : 662-667.
-
2Enriquez J, Gallego A, Torras X, et al. Retreatment for 24 vs 48weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepatitis,2000,7 : 403-408.
-
3Cavalletto L, Chemello L, Donada C, et al. The pattern of response to interferon alpha (alpha-1FN) predicts sustained response to a 6-month alpha IFN and ribavirin retreatment for chronic hepatitis C.J Hepatol,2000,33 : 128-134.
-
4lyoda K, Yuki N, Kato M, et al. Retreatment with interferon for chronic hepatitis C after transient response. J Clin Gastroenterol,2000, 31:297-301.
-
5Arase Y, lkeda K, Chayama K, et al. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course. J Gastroenterol,2000,35 : 607-612.
-
6Watanabe K, Yoshioka K, Terazawa Y, et al. A patient with chronic hepatitis C who obtained sustained response by retreatment of interferon after decrease of viral load and mutation in interferon sensitivity determining region. Intern Med,2001,40 : 489-492.
-
7Dettmer RM, Reinus JF, Clain DJ, et al. Interferon-alpha-2b and ribavirin for retreatment of chronic hepatitis C. Hepatogastroenterology,2002, 49 : 758-763.
-
8Fattovich G, Zagni 1, Fornaciari G, et al. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. J Viral Hepatitis,2003,10 : 111-117.
-
9Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology,1999,30 : 787-793.
-
10Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology,2002,36 : $237 244.
-
1Paulon E,Naoumov NV.慢性丙型肝炎的个体化抗病毒疗法[J].中国处方药,2006(5):21-21.
-
2张原青,郭津生.HALT-C试验及其相关研究主要进展[J].肝脏,2013,18(10):693-698.
-
3古月.蛋白酶抑制剂突变的数量和类型可决定病毒学反应[J].国外医学情报,2006,27(7):23-23.
-
4Sarrazin C.,Berg T.,Weich V.,W. Siffert,陈瑜.GNB3基因C825T多态性和丙型肝炎1型患者对干扰素-α/利巴韦林治疗的反应[J].世界核心医学期刊文摘（胃肠病学分册）,2005,0(12):45-46.
-
5周兆群.干扰素联合山莨菪碱及叶酸治疗轮状病毒性肠炎的临床观察[J].海南医学,2006,17(11):1-1.
-
6聂青和,程勇前.慢性丙型病毒性肝炎的诊断与治疗[J].世界华人消化杂志,2004,12(10):2382-2385. 被引量：7
-
7周忠.7例带状疱疹诱发慢性阻塞性肺疾病急性加重患者的临床分析[J].中国民康医学,2015,27(6):78-79. 被引量：2
-
8丁玲.小剂量丙种球蛋白治疗手足口病疗效观察[J].中外医学研究,2012,10(9):98-98. 被引量：2
-
9徐静,刘景娥,王德智,贾洪,李丽萍.SARS的饮食护理[J].天津中医药,2003,20(3):69-69.
-
10刘慧君.早期病毒学反应对IFN-α抗病毒疗效的预测[J].实用药物与临床,2005,8(2):34-34.
